| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | RB1; Retinoblastoma-associated protein; p105-Rb; pRb; Rb; pp110 |
| Entrez GeneID | 5925 |
| WB Predicted band size | Calculated MW: 106 kDa; Observed MW: 106 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Retinoblastoma around the phosphorylation site of Ser780. AA range:751-800 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于Phospho-Rb (Ser780)抗体的3篇参考文献，按文献名称、作者和摘要内容简要概括：
1. **"Phosphorylation of RB at Serine 780 is a marker of RB inactivation in human cancer"**
- **作者**: Knudsen ES, et al.
- **摘要**: 该研究利用Phospho-Rb (Ser780)抗体检测多种癌症组织中Rb蛋白的磷酸化状态，发现Ser780位点的磷酸化与CDK4/6活性升高相关，可作为Rb功能失活的标志，尤其在乳腺癌和神经母细胞瘤中具有预后意义。
2. **"Distinct phosphorylation sites on Rb regulate E2F binding and apoptosis"**
- **作者**: Zarkowska T, et al.
- **摘要**: 通过Phospho-Rb (Ser780)抗体分析不同磷酸化位点的功能差异，发现Ser780磷酸化特异性地削弱Rb与E2F的结合能力，促进细胞周期进程，而其他位点(如Ser807/811)则与凋亡信号调控相关。
3. **"CDK4/6 inhibition specifically suppresses phosphorylation of RB at Serine 780 in HER2+ breast cancer"**
- **作者**: Torres-Guzmán R, et al.
- **摘要**: 研究使用Phospho-Rb (Ser780)抗体验证CDK4/6抑制剂(如Palbociclib)对HER2阳性乳腺癌细胞的作用，发现药物处理后Ser780磷酸化水平显著降低，伴随细胞周期G1期阻滞，提示该抗体可用于靶向治疗的效果监测。
4. **"A novel role for RB phosphorylation in DNA damage response"**
- **作者**: Baus F, et al.
- **摘要**: 通过Phospho-Rb (Ser780)抗体发现，DNA损伤后Rb在Ser780位点的磷酸化被ATM激酶调控，可能参与细胞周期检查点激活，挑战了传统认为CDK4/6是唯一调控该位点的激酶的观点。
以上文献涵盖癌症机制、药物研究和信号通路解析，均直接应用Phospho-Rb (Ser780)抗体进行功能或临床相关性分析。
The Phospho-Rb (Ser780) antibody is a crucial tool for studying cell cycle regulation and tumor suppressor pathways. Retinoblastoma protein (Rb), encoded by the *RB1* gene, is a key regulator of the G1-S phase transition. In its unphosphorylated state, Rb binds and inhibits E2F transcription factors, blocking cell cycle progression. Phosphorylation at specific residues, including Ser780. inactivates Rb by promoting its dissociation from E2F, enabling S-phase entry. This phosphorylation event is primarily mediated by cyclin-dependent kinase 4/6 (CDK4/6) complexes with cyclin D, making Ser780 a marker of CDK4/6 activity.
The Phospho-Rb (Ser780) antibody specifically detects Rb phosphorylated at serine 780. allowing researchers to assess CDK4/6 activation status and Rb pathway functionality. It is widely used in cancer research, as dysregulation of the CDK-Rb-E2F axis is common in malignancies. For example, hyperphosphorylation of Rb due to CDK4/6 hyperactivity or *RB1* mutations drives uncontrolled proliferation. The antibody is also employed in preclinical studies to evaluate CDK4/6 inhibitors (e.g., palbociclib) and monitor therapeutic responses.
Validated in applications like Western blotting, immunohistochemistry, and flow cytometry, this antibody helps elucidate mechanisms underlying cell cycle control, oncogenesis, and drug resistance. Its specificity for the phosphorylated epitope ensures accurate detection of Rb inactivation, making it indispensable for studies linking Rb phosphorylation status to disease progression or treatment outcomes.
×
